Loading...
•
Jun 30, 2023
BioCryst Q2 2023 Earnings Report
Reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.
Key Takeaways
BioCryst's second quarter results show a strong performance with total revenues of $82.5 million, driven by $81.0 million in ORLADEYO net revenue, marking a 24% increase year-over-year. The company is on track to achieve its full-year ORLADEYO revenue target of at least $320 million.
Q2 2023 ORLADEYO net revenue reached $81.0 million, a 24 percent increase year-over-year.
The company is on track to achieve at least $320 million in full-year 2023 ORLADEYO revenue and $1 billion in peak ORLADEYO revenue.
Q2 2023 GAAP EPS was ($0.40), and non-GAAP EPS was ($0.24), excluding a one-time debt extinguishment fee of $29 million.
A clinical trial for BCX10013, a once-daily, oral Factor D inhibitor, is expected to begin enrollment by the end of the year.
Forward Guidance
BioCryst expects full year 2023 global net ORLADEYO revenue to be no less than $320 million. Operating expenses for full year 2023, not including non-cash stock compensation, are expected to be flat to 2022 at approximately $375 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...